Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07518459 | A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144 | PHASE1 | ACTIVE NOT_RECRUITING | 8 | — | — | Feb 11, 2026 | May 28, 2026 | Apr 8, 2026 | 1 | United Kingdom |
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faeces and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity
Identification of greater than 80% of the radioactivity recovered in the urine and/or faeces
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | Participants in Cohort 1 will receive a single intravenous injection of \[14C\]AZD4144 Solution for Infusion |
| Regimen B | EXPERIMENTAL | Participants in Cohort 2 will receive a single oral dose of \[14C\]AZD4144 Oral Solution |
| Name | Type | Description |
|---|---|---|
| [14C]AZD4144 Solution for Infusion | DRUG | Intravenous, fasted |
| [14C]AZD4144 Oral Solution | DRUG | Oral, fasted |
Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * BMI of 18.0 to 32.0 kg/m2 inclusive * Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clin...